Brand Name | Status | Last Update |
---|---|---|
2-oak mix, red/white pollen 3-oak mix, black/blackjack/post pollen 3-ragweed mix, giant/short/western pollen 4-pine mix, austrian/loblolly/scotch/w... | Biologic Licensing Application | 2011-03-11 |
ad incontinence support | C200263 | 2025-03-07 |
avance incontinence care | C200263 | 2024-05-11 |
bioelements, inc. | OTC monograph not final | 2012-01-17 |
ca-rezz - long term care - incontinent cleanser | C200263 | 2024-12-26 |
ca-rezz - norisc - incontinent wash | C200263 | 2024-12-27 |
center-al - acacia longifolia pollen center-al - acer negundo pollen center-al - acer saccharum pollen center-al - agrostis gigantea center-al - al... | Biologic Licensing Application | 2009-06-12 |
chain drug marketing association, inc. | C200263 | 2024-05-21 |
crooked creek distillery inc hand sanitizer | OTC monograph not final | 2020-03-25 |
cvs pharmacy,inc. | C200263 | 2024-08-16 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Coronary disease | D003327 | — | — | — | — | — | 1 | — | 1 |
Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 1 | — | — | 1 |
Dyslipidemias | D050171 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Glioblastoma | D005909 | EFO_0000515 | — | — | 1 | — | — | — | 1 |
Gliosarcoma | D018316 | — | — | — | 1 | — | — | — | 1 |
Astrocytoma | D001254 | EFO_0000271 | — | — | 1 | — | — | — | 1 |
Urinary bladder neoplasms | D001749 | — | C67 | — | 1 | — | — | — | 1 |
Transitional cell carcinoma | D002295 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | — | 1 |
Lymphoma | D008223 | — | C85.9 | 1 | — | — | — | — | 1 |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | — | — | — | — | 1 |
T-cell lymphoma peripheral | D016411 | — | — | 1 | — | — | — | — | 1 |
Lymphoid leukemia | D007945 | — | C91 | 1 | — | — | — | — | 1 |
Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | — | — | — | — | 1 |
Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 1 | — | — | — | — | 1 |
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
Metabolic bone diseases | D001851 | — | — | — | — | — | — | 1 | 1 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 1 | 1 |
Drug common name | Enoblituzumab |
INN | enoblituzumab |
Description | Enoblituzumab is a monoclonal antibody designed for the treatment of cancer. Formerly known as MGA271, the drug is a humanized IgG1κ monoclonal antibody recognizing human B7-H3, a member of the B7 family of immune regulators.
|
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL3545373 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | M6030H73N9 (ChemIDplus, GSRS) |